Home

Content about Atrial Fibrillation

07.02.09
FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation

The U.S. Food and Drug Administration has approved Multaq tablets (dronedarone) to help maintain normal heart rhythms in patients with a history of atrial fibrillation or atrial flutter (heart rhythm disorders). The drug is approved to be used in patients whose hearts have returned to normal rhythm or who will undergo drug or electric-shock treatment to restore a normal heart beat.

04.09.09
Merck Co., Inc. and Cardiome Sign License Agreement for Vernakalant, an Investigational Drug for Treatment of Atrial Fibrillation

Merck Co., Inc. and Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced a collaboration and license agreement for the development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation.

04.08.09
Novel Medical Imaging Technique May Enable Physicians To Predict Treatment Outcomes In Patients With Atrial Fibrillation

University of Utah researchers have found that delayed-enhancement magnetic resonance imaging (DE-MRI) holds promise for predicting treatment outcomes and measuring disease progression for patients with atrial fibrillation (AF), a little known heart rhythm disorder that affects more than 3.5 million Americans and causes more than 66,000 deaths a year. Their latest study on a novel application of this technology for AF appears in the April 7 issue of the journal Circulation.

04.02.09
Plavix(R) Plus Aspirin More Effective Than Aspirin Alone In Preventing Major Vascular Events In Patients With Atrial Fibrillation

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today new findings from a landmark investigational study that demonstrated that, for patients with atrial fibrillation who were at increased risk for stroke and could not take an oral anticoagulant (OAC) medication, taking Plavix® (clopidogrel bisulfate) in addition to aspirin significantly reduced major vascular events by 11% over aspirin alone, at a median of 3.6 years of follow-up (6.

04.02.09
Plavix(R) Plus Aspirin More Effective Than Aspirin Alone In Preventing Major Vascular Events In Patients With Atrial Fibrillation

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today new findings from a landmark investigational study that demonstrated that, for patients with atrial fibrillation who were at increased risk for stroke and could not take an oral anticoagulant (OAC) medication, taking Plavix® (clopidogrel bisulfate) in addition to aspirin significantly reduced major vascular events by 11% over aspirin alone, at a median of 3.6 years of follow-up (6.

04.01.09
Aspirin With Plavix Reduced Stroke Risk, Study

A large new study found that taking aspirin with clot busting drug Plavix (clopidogrel) cut the risk of stroke by 28 per cent in patients with irregular heart rhythms (atrial fibrillation) who were not able to take anticoagulants like warfarin.

03.21.09
Boehringer Ingelheim`s Novel Oral Anticoagulant Dabigatran Etexilate Is The Frontrunner For Stroke Prevention In Atrial Fibrillation

Boehringer Ingelheim announced that the last patient has completed treatment in the landmark phase III Randomized Evaluation of Long term Anticoagulant therapy (RE-LY®) study.

03.21.09
Cardiac Arrythmias Are Often Accompanied By Sleep-Disordered Breathing

Breathing during sleep is often impaired in patients with atrial fibrillation. In the current edition of Deutsches Arzteblatt International (Dtsch Arztebl Int 2009; 106(10): 164 - 70), Thomas Bitter and his coauthors from the Ruhr University in Bochum investigate how often sleep-disordered breathing occurs in this form of cardiac arrythmia and what the different types are.